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underestimation of resource use costs. ConClusions: The study findings indicate 
that manufacturers should consider providing data supporting OS benefit versus 
relevant comparators. Also, a robust economic model including sensitivity analysis 
to adjust for uncertainties, and incorporating appropriate cost and utility values 
could be beneficial to gain access in CEA markets.
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objeCtives: Patient-reported outcomes (PROs) are designed to measure the unique 
patient perspective on an aspect(s) of a disease or the impact of treatment. After the 
development and validation of a PRO measure, often the next step is to understand 
how the PRO scores and changes are related to the clinical endpoints in order to 
better inform and interpret the newly developed PRO for clinician use or to provide 
greater insights into disease burden or treatment efficacy. Our objective is to review 
commonly used statistical Methods when assessing the association of PRO and 
clinical endpoints and to introduce alternate statistical applications. Methods: 
A review of the literature revealed several statistical Methods used to define and 
quantify the association between PROs and clinical endpoints including correlation 
analysis, responder/categorical analysis, linear and logistic regression and receiver-
operating curves. However, these methodologies typically examine the relationship 
at a single time-point, ignoring the longitudinal nature of the study design. Our 
research will use simulated longitudinal data to examine the association between 
PROs and clinical endpoints across multiple time-points and introduce alternate 
applications using mixed-models for repeated measures. We will provide a series of 
examples based on the simulated data to show how each method uniquely demon-
strates the relationship between these endpoints. ConClusion: To help stakehold-
ers understand the relevance of PROs, it is often an important step to assess the 
association of a PRO to existing clinical endpoints. Our research introduces alternate 
approaches to examine this association across multiple time-points which account 
for the longitudinal design found in most trials.
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bACkground: In many cases, medicines for ultra-rare disorders (URDs) have high 
acquisition costs and are associated with incremental cost per quality-adjusted 
life year (QALY) gained exceeding widely used benchmarks for cost effective-
ness. objeCtives: To address the underlying reasons why interventions for URDs 
often fail to meet conventional benchmarks for cost effectiveness and deliberate 
implications for formal Health Technology Assessments (HTAs) including economic 
evaluation. Methods: An international group of experts in health economics, med-
ical ethics, evidence-based medicine (EBM), and HTA met in conjunction with the 
Annual European ISPOR Congresses in November 2012, 2013, and 2014. results: 
In contrast to the principles of EBM, the logic of cost effectiveness (including bench-
marks for incremental cost per QALY gained, as applied by some HTA agencies as a 
measure of “value for money”) does not adequately capture well-established social 
norms and preferences regarding health care resource allocation. Such preferences 
include, but are not limited to, a priority for care for the worst off (related to initial 
health state), for those with more urgent conditions (the so called “rule of rescue”), 
and a relatively lower priority based upon capacity to benefit, as well as a dislike 
against “all or nothing” resource allocation decisions that might deprive certain 
groups of patients from any chance to access effective care. ConClusions: The 
group concluded that there exists a strong need for an improved or new paradigm to 
assess value for money. Candidates include direct social value measurement using 
the relative social willingness-to-pay or person trade-off instruments, combined 
with a greater role for budget impact analysis. As a pragmatic interim alternative, 
multi-criteria decision analysis may prove useful. Further systematic research into 
social preferences, including their valid measurement, should be prioritized relative 
to the continued application of a descriptively flawed framework based on bench-
marks for maximum incremental cost per QALY gained.
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objeCtives: To describe a framework for the integration of encompassing models of 
value into health technology assessment (HTA) decision processes, and to use this to 
work through the implications of implementing broader models of value, using an 
‘end-of-life premium’ as an exemplar proposition. Methods: Building on a scoping 
review of the literature on the role of values in HTA and the use of cost-effectiveness 
objeCtives: Patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors harbor exon 19 deletions or exon 21 (L858R) substitution mutations in the 
epidermal growth factor receptor (EGFR) gene are eligible for first line treatment 
with erlotinib or afatinib, tyrosine kinase inhibitors (TKIs) approved for use in the 
U.S. The relative clinical and economic impacts between these two agents remain 
unclear. Methods: A Markov model was developed in which patients could transi-
tion through three health states: Pre progression, progression, and death. Transition 
probabilities were derived from key clinical trials, peer-reviewed literature, and U.S. 
life tables. We assumed a progression free survival (PFS) hazard ratio (HR) of 1 in 
the base case, and a scenario analysis was performed using data from an indirect 
treatment comparison in which the PFS HR for erlotinib vs. afatinib was 0.44. Costs 
included those related to drug utilization, drug administration, and adverse events. 
We calculated the discounted (3%) incremental life expectancy, quality-adjusted 
life expectancy, and costs from a U.S. payer perspective. Probabilistic sensitivity 
analysis (PSA) was conducted to assess parameter uncertainty. results: Initiating 
treatment with erlotinib rather than afatinib resulted in comparable QALYs and 
modest decreased costs (-$895) in the base case. PSA indicated that at a threshold 
of $100,000/QALY, there was approximately a 60% probability that erlotinib is cost-
effective. In the scenario analysis (PFS HR: 0.44) we found that erlotinib treatment 
resulted in $35K greater costs and 0.274 additional QALYs gained, resulting in an 
ICER of $128K/QALY. ConClusions: Our analysis indicates that first-line treatment 
with erlotinib vs. afatinib may lead to similar quality adjusted life years gained but 
slightly lower costs. Depending on assumptions about the comparative effective-
ness, erlotinib may be in the range of being cost effective compared to afatinib, even 
with significantly longer PFS and treatment duration.
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objeCtives: To analyze all available clinical trial evidence to determine whether 
dose-intensive therapy Results in longer overall survival (OS) or progression-free 
survival (PFS) in DHL patients who have poorer prognoses than standard-risk diffuse 
large B-cell lymphoma patients. Methods: Eleven observational studies evaluat-
ing first-line treatments in 401 adult DHL patients were included (no randomized 
trials were available). Individual patient data (IPD) were obtained from authors of 2 
studies; IPD was extracted from digitized Kaplan-Meier survival curves of 3 studies. 
Median survival (n= 4) and percent survival at month 24 (n= 2) were available from 
the remaining publications. All data types were synthesized within a random-effects 
Weibull proportional hazards model using a Bayesian analysis framework to esti-
mate OS and PFS of each treatment. IPD points were given Weibull distributions, cen-
sored as necessary. The number of survivors at median or month 24 was estimated 
from the total number of patients and assumed binomially distributed. The binomial 
probabilities were then used to inform the Weibull survival parameters. Treatments 
of interest were R-CHOP (standard dose), R-EPOCH (intermediate dose), and R-Hyper-
CVAD or R CODOX-M/R-IVAC (dose-intense [DI]). results: Appropriateness of the 
Weibull and proportional hazards assumptions was verified by graphical tests using 
the available IPD. Estimated hazard ratios (HRs) of OS (n= 374) relative to R-CHOP 
were 0.77 (95% credible interval: 0.51-1.13) for R-EPOCH and 0.89 (0.62-1.27) for DI, 
indicating no significant differences for either higher-dose treatment. R-EPOCH, 
but not DI, was associated with a marginally significant increase in PFS (n= 357) 
with HRs of 0.66 (0.44-0.96) and 0.74 (0.51-1.05), respectively. ConClusions: This 
novel methodology combines several data types, allowing synthesis of data from 
a larger number of studies than could have been possible with standard analysis 
techniques. The totality of the available published data suggested R-EPOCH chemo-
therapy extended PFS, but not OS in DHL patients.
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REiMBURSEMENT dECiSiON LANdSCAPE fOR METASTATiC BREAST CANCER 
ThERAPiES: A COMPARiSON Of fACTORS LEAdiNg TO fAvORABLE ANd 
UNfAvORABLE RECOMMENdATiONS ACROSS LEAdiNg hTA AgENCiES
Banerjee P., Gupta J., Kumar P., Kapoor A., Mazumder D.
Optum Global Solutions, Noida, India
objeCtives: To compare the reimbursement recommendations and ration-
ale for decisions for metastatic breast cancer therapies across seven HTA agen-
cies. Methods: We assessed HTA reports published by AHRQ, HAS, IQWiG, NICE, 
PBAC, pCODR and SMC for metastatic breast cancer therapies. Decisions were cat-
egorized as positive, negative or deferred, and recommendation summaries were 
analyzed to identify clinical and economic factors affecting decisions. results: 
Thirty-nine HTA reports were identified, of which 46% had a positive recommenda-
tion. No relevant HTA reports were published by AHRQ. Highest positive decisions 
were provided by pCODR (80%), all being conditional on improving cost-effectiveness 
to an acceptable level. Major factors driving positive decisions were overall survival 
(OS) benefit for IQWiG and pCODR; acceptable efficacy and safety for HAS; and 
cost-effectiveness versus relevant comparator(s) for NICE, PBAC and SMC. Highest 
percentage of negative decisions was provided by NICE (75%). HAS cited lack of 
survival benefit (OS or progression-free survival) or quality-of-life improvement, 
or unacceptable safety profile for negative decisions; whereas, pCODR and IQWiG 
mainly considered lack of OS benefit and inappropriate comparators. Negative 
decisions by NICE, PBAC and SMC were mainly due to economic modelling issues 
that resulted in high ICERs. NICE also considered lack of quality-of-life benefit and 
unacceptable safety profile for negative decisions. Major economic modelling issues 
across HTA agencies included inappropriate extrapolation of immature OS data, 
carry-over of benefit into post-treatment states, improper cross-over adjustment, 
non-inclusion of adverse event-related disutilities and costs, underestimation of 
post-progression utility and costs, overestimation of comparator drug costs, and 
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objeCtives: In randomized controlled trials, differences in prognostic factors 
– whether statistically significant or not – contribute to absolute differences in 
outcomes. Absolute differences are at the heart of economic evaluation. Economic 
modelling may help increase precision of incremental differences, despite ran-
domization. The objective of the present study was to describe the effect of 
economic modelling techniques on the magnitude and precision of economic 
and decision outcomes using a RCT-based economic evaluation. Methods: An 
economic evaluation was conducted alongside a RCT (n= 350) in diagnostic inter-
ventional cardiology. Raw unadjusted total costs and QALYs were assembled at 
the individual level using resource use and EQ5D responses. For economic mod-
elling, outcomes were then conditioned according to the diagnosis and fit with 
generalized linear models, adjusting for baseline characteristics. Total costs and 
QALYs were then estimated using marginal prediction with the fitted models. 
Family and link functions were selected using the Modified Park’s and Pregibon 
Link test, respectively. Uncertainty in GLM coefficients, unit cost parameters 
and sampling were incorporated using bootstrapping and Monte Carlo meth-
ods. results: The magnitude and direction of incremental costs were compa-
rable between the raw vs. modelled results (-£132 vs. -£204). However, precision 
increased considerably; the 95%CI reduced by 44% ([-£1772 to £817] vs. [-£1437 to 
£30]). Incremental QALYs also showed comparable magnitudes (0.013 vs -0.005), 
though the direction reversed, albeit by a non-important magnitude. As well, the 
95%CI of incremental QALYs reduced by 83% ([-0.033 to 0.060] vs. [-0.015 to 0.001]). 
Reduction in joint incremental cost-effect uncertainty was also apparent upon 
visual inspection of the cost-effectiveness plane. Decision (cost-effectiveness) 
uncertainty was comparable across the common willingness-to-pay thresholds 
(~70% at £0-£30,000/QALY). ConClusions: Economic modelling can increase pre-
cision in economic outcomes and reduce uncertainty in decision making, support-
ing the results and decision arising from a raw unadjusted economic evaluation 
alongside a RCT.
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objeCtives: Economic evaluations of competing interventions often estimate 
mean overall survival (OS) as a measure of intervention effect. New treatments 
offer some patients the possibility of being “cured” of their disease, in that they 
become long-term survivors whose risk of death is the same as a disease-free per-
son. Grouping cured and non-cured patients together and reporting one mean value 
for OS may provide a biased assessment of a therapy that cures a proportion of 
patients. In this study, we compared standard survival analysis versus an approach 
that accounts for the fraction of patients cured. Methods: We used clinical trial 
data from advanced melanoma patients treated with ipilimumab (n= 137) versus 
gp100 (n= 136) and applied statistical methodology for mixture cure models. We used 
logistic regression to model the probability that a patient was cured and a Weibull 
regression model to estimate the excess mortality for non-cured patients. Both 
cured and non-cured patients were subject to background mortality not related to 
cancer; we calculated this using age- and gender-matched mortality data from US 
Social Security life tables. results: Ignoring a cured proportion, ipilimumab had 
an estimated mean OS that was 8 months longer than gp100. Cure model analy-
sis showed that the proportion of cured patients drove this difference, with 20% 
cured on ipilimumab compared to 6% with gp100. The mean OS among non-cured 
patients was 5 months on ipilimumab versus 4 months on gp100. The mean OS 
among cured patients was 26 years on both arms. After adjusting for covariates, 
ipilimumab had an improved cure proportion compared to gp100 (OR= 2.01, 95% CI 
(1.00, 4.06)), but there were no significant differences in survival among non-cured 
patients (HR= 1.05, 95% CI (0.80, 1.38)). ConClusions: This analysis supports using 
cure modeling in health economic evaluation in advanced melanoma, since it may 
reduce bias in OS estimates.
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objeCtives: Methodologies and information systems associated with health 
intervention costs in Canada have evolved since the Guidance Document for the 
Costing Process was published in 1996. This document was produced to assist 
researchers undertaking economic studies of health interventions in Canada. To 
ensure this document is useful to researchers the Canadian Agency for Drugs 
and Technologies in Health (CADTH) is undertaking a major update of the docu-
ment. This presentation will provide an overview of the key changes to the 
document, based on the availability of new information sources and methodolo-
gies. Methods: A literature review of Canadian economic evaluations published 
between 2011 to 2014 was conducted by CADTH to understand how cost infor-
mation is currently being used by researchers. In addition, CADTH conducted a 
scan of the various costing and resource use methodologies used in health care 
in Canada, and undertook discussions with researchers in health costing. Based 
on the information obtained, required revisions and additions to the Guidance 
Document were identified. results: The updated Guidance Document con-
sists of eight sections: Pharmaceuticals, Physician Services, Hospital Services, 
Diagnostic and Investigational Services, Non-Physician Professional Services, 
Community Based Services, Informal Caregiver Costs, and Other Information. 
These categories give way to targeted subsections, for which, detailed descrip-
tions of cost components are provided, along with relevant data sources and 
guidance as to how and when researchers can apply the data. Key additions to 
this update include: the inclusion of newer methodologies (e.g., CMG+ costing, 
thresholds for reimbursement decisions, we describe a model for ensuring that 
opportunity cost is appropriately captured in the willingness-to-pay value. We 
then show how the modified model would impact upon coverage decisions which 
include an ‘end-of-life premium’. results: We identify four broad categories of 
value premia. We characterise the importance of locating opportunity cost factors 
(including price and budget impact) outside the value framework. We then describe 
a structural process for ensuring that the value framework is applied equally to the 
identified beneficiaries of a technology and the frequently unidentified individuals 
who will bear the opportunity cost, in order to promote horizontal equity in HTA 
processes. Finally, we show how the conventional approach to incorporating value 
premia, such as the ‘end-of-life premium’, promotes inefficient and inequitable 
resource allocation decisions. ConClusions: The conventional HTA model does 
not adequately reflect the social value of health care. However, naïve modifications 
to the cost-effectiveness threshold lead to both inefficient and inequitable resource 
allocation decisions. It is important that modified value frameworks are applied 
equally to the identified beneficiaries of a technology and those individuals who 
bear the opportunity cost.
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objeCtives: The U.S. Agency for Healthcare Research and Quality (AHRQ) solicited 
the development of guidance for modeling and simulation studies conducted in the 
context of health technology assessment. Methods: We updated and expanded 
existing systematic reviews of recommendations for the conduct and reporting 
of modeling and simulation studies in healthcare. We also solicited input from a 
multidisciplinary team of clinical, policy, and decision analysis experts. The Results 
of the systematic review were then discussed in person with a panel of 28 stake-
holders including patient representatives, providers and purchasers of care, payers, 
policy makers, and principal investigators. Stakeholders commented on existing 
recommendations and identified gaps, limitations, and areas for elaboration. We 
subsequently reviewed the websites of 126 health technology assessment organiza-
tions that provide guidance on the conduct and reporting of decision and simula-
tion models. We sought additional input from senior researchers with experience 
in modeling and simulation within AHRQ and its Evidence-based Practice Centers, 
and from external reviewers. results: We developed principles and good practice 
recommendations for modeling and simulation studies conducted to enhance and 
contextualize the findings of systematic reviews. The guidance applies to struc-
tural mathematical models and simulation experiments based on such models. 
The recommendations address model identification, estimation, and evaluation, 
as well as the use of sensitivity, stability, and uncertainty analyses throughout 
model development and use. Recommendations are organized by whether they 
pertain to the model conceptualization and structure, data, consistency, or the 
interpretation and reporting of Results. We provide the rationale for each recom-
mendation, with supporting evidence or, when adequate evidence was lacking, 
best judgment. ConClusions: We present systematically developed guidance for 
modeling and simulation in the context of health technology assessment. We are 
hopeful that this work will contribute to increased use of modeling and simulation 
in conjunction with systematic reviews.
RESEARCh ON COST STUdiES METhOdS
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objeCtives: To explain the relevance of and provide guidance for using a new cost 
metric, the National Average Drug Acquisition Cost (NADAC) for US based economic 
evaluations. The key feature of NADAC is that a single cost is reported for a unit of 
all pharmaceutically equivalent drugs. The cost is an average of the per unit cost 
paid by the current month’s national sample of retail pharmacies. Methods: We 
propose a costing procedure and provide a detailed overview of costing for five 
diverse drugs and compare estimates to AWP, the current metric used as an estimate 
for acquisition cost. With data from 2014 and enumerated specific National Drug 
Codes (NDC) included in each estimate, we used the July cost as the base-case and 
the range observed over the year as a measure of uncertainty. For AWP we used its 
value on July 1. To eliminate the impact of obsolete NDCs we only considered the 
AWPs of NDCs that had an associated NADAC in 2014. The base-case was estimated 
as the average of AWP across equivalent NDCs and the range was the low and high 
AWP. results: In one example, 500mg cephalexin had a NADAC of $0.09662 in July. 
This cost was based on 22 NDCs and was updated 11 times throughout the year. The 
range was [$0.08877, $0.12138] per unit. By contrast the distribution of AWPs for the 
same 22 NDCs had an average of $1.35606 and range of [$1.2259, $1.376]. In other 
drugs the ratio of NADAC and AWP ranged from 7-89%. ConClusions: NADAC 
has limitations, but appears to provide a better estimate of true drug acquisition 
cost than AWP. Given the wide discrepancy observed between NADAC and AWP it 
appears using AWP, even discounted, may introduce bias in economic evaluations.
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